For more information on this report please contact ediz.ibrahim@visiongain.com (+44 (0) 2075499976) or refer to our website http://www.visiongain.com/Report/1157/Brazilian-Pharmaceutical-Market-2014-2024

1. Brazilian Pharmaceutical Market
2014-2024
©notice
This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.

2. Contents
1. Executive Summary
1.1 Overview of Findings
1.2 Chapters in the Report
1.3 Research and Analysis Methods
2. Overview of the Brazil Pharmaceutical Market, 2014-2024
2.1 Market to Continue Strong Performance to 2024
2.2 The Sixth-Largest Economy in the World in 2012
2.2.1 Population Size the Biggest Driver for the Market
2.2.2 Generics Segment Continues to Grow in Importance
2.2.3 CNS Remains the Largest Therapeutic Area in 2012
2.2.4 Three Domestic Companies in Top Six for 2012
2.3 Why the Brazilian Market Matters: Regional and Global Market Context
2.3.1 Brazil Represented 46% of the Latin American Market in 2012
2.3.2 Brazil as Part of the BRIC/’Pharmerging’ Markets in 2013
2.3.2 Brazil as Part of the BRIC/’Pharmerging’ Markets in 20132.5.6 Other Players in the
3. Brazilian Healthcare: Commercial Overview, 2014-2024
Market2.8.1 The Vaccines Market
3.1 ANVISA The Key Institutional Body
3.1.1 Other Important Agencies
3.2 Over 62% Supplement SUS with Private Healthcare
3.2.1 CMED Adjusts Prices Up for 2013
3.2.2 Reimbursement for RENAME Drugs via Farmácia Popular
3.2.3 Private Insurance Market Growing, but Costs for Insurers Rising
3.3 M&A-Led Consolidation Continues in Both Wholesale and Retail Sectors
3.3.1 Celesio-Owned Panpharma Still the Top Distributor
3.3.2 RaiaDrogasil, Brazil Pharma and Other Major Chains Hold 47% of Retail Sector
3.3.3 Marketing Spend in Brazil Approaches $5bn
www.visiongain.com

3. Contents
3.4 A Nation of Contrasts: Healthcare Variations in the Brazilian Regions
3.4.1 Southeast: Over 40% of the National Population, But Over Half of Pharmaceutical Market
Revenues
3.4.2 Northeast: Shortest Life-Expectancies and Second-Highest Market Share
3.4.3 South: Smallest Region with Highest Per Capita GDP
3.4.4 MidWest: Landlocked Region with Lowest Population
3.4.5 North: Largest and Poorest Area Represents <5% of Market
4. Product Mix in the Brazilian Market, 2014-2024
4.1 How Much Ground Will Generics Gain by 2024?
4.2 Patented Pharmaceuticals: Still the Basis of the Brazil Market
4.2.1 PDPs and HTA: Government Attempts to Regulate Costs
4.2.2 The Battle for Biomanufacturing Capabilities
4.2.3 Can BioNovis and Orygen Build on Aché’s Biosimilar Advances?
4.2.4 At 55% More Expensive, Can Patented Products Hold Off the Generics Revolution?
4.2.5 Market Forecast for Prescription Pharmaceuticals, 2014-2024
4.3 Generic Pharmaceuticals: Rapid Expansion Since 2000
4.3.1 Pró-Genéricos Anticipate 45% Market Capture
4.3.2 The Issue of Non-Bioequivalent Drugs
4.3.3 Counterfeits: Believed At Least 7% of Brazil's Drug Supply Affected
4.3.4 Generics Opportunity Not Yet Fully Harnessed
4.3.5 Market Forecast for Generic Pharmaceuticals, 2014-2024
4.4 OTC Segment: Still Favoured by Brazilian Consumers
4.4.1 Coming Out From Behind the Counter
4.4.2 Advertising: ABIMIP Lobbies on DTC Restrictions
4.4.3 Vitamins and Minerals Purchased by ~15% of Brazilians
4.4.4 From Analgesics to Erectile Dysfunction Treatments, Consumer Health Treatments Remain
Prominent in the Market
4.4.5 Market Forecast for the OTC Segment, 2014-2024
www.visiongain.com

4. Contents
4.4.5 Market Forecast for the OTC Segment, 2014-2024
5. Therapeutic Areas in the Brazil Market, 2014-2024
5.1 Oncology to Overtake CNS Diseases by 2024
5.2 The Rise of Non-Communicable Diseases
5.3 CNS Conditions: Disease Burden Comparable to US
5.3.1 Domestic Companies Target OTC and Generic Pain Relief
5.3.2 Foreign Competition in the Analgesics Area
5.3.3 Prevalence of 10%+ Represents Major Opportunity in Antidepressant Space
5.3.4 CNS Conditions: A Therapeutic Area with Unique Relevance to Brazil
5.3.5 Market Forecast for CNS Therapeutic Area 2014-2024
5.4 Cardiovascular Diseases: Brazil’s Biggest Killer
5.4.1 Anti-hypertensives: One of the Nation’s Key Drugs
5.4.2 Decline of the Statins
5.4.3 Ache and Sanofi Among the Key Players in This Field
5.4.4 The Heart Disease Opportunity over the Next 10 Years
5.4.5 Market Forecast for Cardiovascular Therapeutic Area 2014-2024
5.5 Alimentary/Metabolic Diseases: Affecting More Than a Third of Brazilians
5.5.1 Lack of Diabetes Awareness Still an Issue
5.5.2 Biosimilar Insulins to Play an Important Role
5.5.3 EMS’ Generic Esomeprazole an Important Addition
5.5.4 Capturing the Alimentary/Metabolic Disease Opportunity
5.5.5 Market Forecast for Alimentary/Metabolic Therapeutic Area 2014-2024
5.6 Oncology: To Become the Biggest Therapeutic Area?
5.6.1 Breast Cancer Has the Highest Prevalence in Brazil
5.6.2 Biosimilars to Help Widen Medicine Access
5.6.3 Eurofarma, Cristalia and Libbs the Domestic Leaders
5.6.4 Will the Oncology Therapeutic Area Realise its Potential?
5.6.5 Market Forecast for Cancer Treatment 2014-2024
5.7 Infectious Diseases: Brazil Faces Unique Challenges
5.7.1 PPDs to Meet Vaccines Need
www.visiongain.com

5. Contents
5.7.2 Brazil Managing HIV Despite IP Concerns
5.7.3 Chagas Disease and Other Infectious Disease Concerns
5.7.4 Infectious Disease: The Past or the Future for Brazilian Pharma?
5.7.5 Market Forecast for Infectious Disease Treatment, 2014-2024
5.8 Other Therapeutic Areas
6. Domestic Companies in the Brazilian Market, 2014-2024
6.1 EMS Continues to Lead the Field with 8% Market Share
6.2 Purchase of Medley Means Multinationals Still Own Bulk of Market
6.2.1 Domestic Firms Control 70% of Generics Market
6.3 EMS Pharma: First Among Brazilian Generics Firms
6.3.1 Significant R&D, Manufacturing and Sales Capabilities
6.3.2 Targeting Expansion Oversees
6.3.3 Legrand and Germed Key Subsidiaries of EMS
6.4 Medley: Foreign-Owned Generics Leader Maintains 8% Market Share in 2012
6.5 Hypermarcas: Diversified Drugstore Chain
6.5.1 Neo Química Genericos: Third-Ranked in Generics Segment
6.5.2 Other Key Hypermarcas Subsidiaries Include Brainfarma
6.5.3 Hypermarcas Performance in 2012
6.6 Aché: The Major Acquisition Target in Brazil
6.6.1 Cardiovascular Drugs the Main Focus
6.6.2 Ache: Possible M&A?
6.6.3 A Large Domestic Merger an Alternative Possibility?
6.7 Laboratorios Eurofarma: Diversified Leader with Hospital, Generic and Veterinary Business
Units
6.7.1 Vigorous Latin American Acquisitions Policy
6.7.2 Strong Presence in Cancer Treatment
6.8 Laboratorio Teuto Brasileiro: Largest Pharmaceutical Complex in Latin America
6.8.1 Melcon Partnership and Other Growth Strategies for Teuto
www.visiongain.com

6. Contents
6.9 Biolab-Sanus Farma: 100+ Products, Four Exclusive
6.9.1 Collaborations with Emcure and Merz
6.10 Laboratório Cristália: R&D Leader
6.10.1 Leader in API Manufacturing
6.10.2 Involved in Nearly Half of All PDP Arrangements
6.11 Libbs Farmacêutica: Key Player in Cancer Treatment
6.11.1 Working on a Biosimilar – Opening New Possibilities
6.12 Uniao Quimica Farmaceutica Nacional: Expanding in Minas Gerais
6.13 Other Domestic Players
6.14 The Major Biosimilar Collaborations
6.14.1 BioNovis: Aiming at Commercialisation by 2015
6.14.2 Orygem Biotecnologia
6.15 Other Potential Sources of Innovation
6.15.1 Fundação Oswaldo Cruz: At the Heart of PDP
6.15.2 ANVISA Reform of Brazilian Patent System
7. Multinational Companies in the Brazilian Market, 2014-2024
7.1 M&A Propels Sanofi into First Position
7.2 Multinational Investment in the Market Continues to Grow
7.3 Sanofi: Medley Purchase Makes French Giant the Outright Leader
7.3.1 Genzyme and Consumer Health the Main Growth Drivers
7.3.2 Generics Sales Stall in 2012
7.3.3 Inventory and 2013 Results
7.4 Novartis: Brazil Now Sixth-Largest Market
7.4.1 Sandoz Sales Grow by 29% in 2012
7.4.2 Pricing and Reimbursement Solutions to Bring Original Drugs to Brazil
7.4.3 Co-operating on Technology Transfer and Other Ideas
7.5 Roche: Double-Digit Brazilian Growth in 2012
7.5.1 Positioned to Tap the Oncology Opportunity
www.visiongain.com

7. Contents
7.5.2 Herceptin, Pricing and Reimbursement
7.6 Merck & Co. – Long-Standing Presence in the Brazilian Market
7.6.1 Gardasil Added to SUS in 2013
7.6.2 ExcelRX JV to Increase Merck’s Standing in Brazil
7.7 Pfizer: Targeting Emerging Market Growth via M&A
7.7.1 Portfolio Ranges from Orphan Biologics to Multivitamins
7.7.2 How Will a Pfizer Break-Up Affect Emerging Market Plans?
7.8 Bayer: Brazil Fifth-Largest Market for Diversified Conglomerate
7.8.1 Consumer Health a Major Focus in Brazil
7.9 AstraZeneca: Struggling with Patent Expiries in Brazil
7.9.1 Possible Future Growth Drivers Include Diabetes
7.10 Boehringer Ingelheim: Pain, Cardiovascular and Respiratory Drugs Bolster Strong National
Portfolio
7.10.1 Technology Transfer Deal for Sifrol
7.11 Takeda: Entering the Top 10 with Multigrip OTC Acquisition
7.11.1 Nycomed Generics and Original Products Also Key to Strategy
7.12 Merck Serono: Over 6% Consumer Health Growth Forecast
7.13 Other Big-Pharma Competitors
7.13.1 Johnson & Johnson: Focusing on Consumer Health and Commodities
7.13.2 GlaxoSmithKline: Vaccines Technology Transfer Opportunities
7.13.3 Abbvie: Humira to Face Biosimilar Challenge in Brazil?
7.13.3.1 Abbott: Generics and Diagnostics-Led Growth Strategy
7.13.4 Eli Lilly: Patent Expiries Hit Emerging Market Revenues.
7.13.5 Bristol-Myers Squibb: Divesting its Brazilian OTC Portfolio Rights
7.13.6 Baxter: Entering Brazilian Haemophilia Market via Tech Transfer
7.13.7 Amgen Signals Brazilian Intent with Bergamo Acquisition
7.13.8 Other Top Biotechs Enter Brazil
7.13.9 Other Top Japanese Companies Trail Behind Takeda in Brazil
7.14 Will Multinational Generics Leaders Compete in Brazil?
7.14.1 Teva Pharmaceutical Industries: Generics Giant Targets Brazil
www.visiongain.com

8. Contents
7.14.2 Mylan: Agile Acquisition Boosts Latin American Strategy
7.14.3 Actavis: Newly-Merged Player to Challenge in Brazil
7.14.4 Ranbaxy Hands Over to Daiichi, but Other Indian Companies Still in the Hunt in Brazil
7.14.5 Glenmark, Strides and Biocon Looking to Enter Brazil
7.14.6 Valeant: Aggressive M&A Drive Into the Market
7.15 Brazil as Research Destination
7.16 Other Multinational Business in Brazil
8. Qualitative Analysis of the Brazilian Market, 2014-2024
8.1 A Crucial Market for the Pharmaceutical Industry?
8.2 Governmental Regulation Remains an Issue
8.3 Room to Expand in Therapeutic Areas and Geographical Regions
8.4 IP Protection: Doubts, Red Tape and Counterfeiting Remain Issues
8.5 Large and Ageing Population Eager to Buy Medicines
8.6 Improved Biotechnology and Digital Among Government’s Goals
8.7 Can Economic Growth Keep Pace With Healthcare Costs?
8.8 Political Environment the Decisive Influence on the Market
9. Conclusions from the Research and Analysis
9.1 Brazil Likely to Outperform Most Other Top 10 Pharma Markets
9.2 Generics to be the Fastest-Growing Segment
9.3 Technology Transfer Crucial to Patented Drugs Market
9.4 Generics and Patented Products: Opportunities for Multinationals
9.5 Anti-cancer Drugs: Biggest Therapeutic and Commercial Opportunity
9.6 Concluding Remarks
www.visiongain.com

9. Contents
List of Tables
Table 1.1 Currency Exchange Rates
Table 2.1 Brazilian Pharmaceutical Market: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 2.2 Brazilian Pharmaceutical Market: Revenues ($m), AGR (%), CAGR (%), 2018-2024
Table 2.3 Product Mix Breakdown: Revenues ($m), Market Share (%), 2012
Table 2.4 Therapeutic Area Breakdown: Revenues ($m), Market Share (%), 2012
Table 2.5 Leading Companies in the Brazilian Pharma Market: Revenues ($m), Market Shares
(%), 2012
Table 2.6 Leading National Markets Worldwide: Revenues ($m), Market Shares (%), 2012
Table 2.7 Leading National Markets in Latin America: Revenues ($m), Market Shares (%), 2012
Table 2.8 Leading National ‘Pharmerging’ Markets: Revenues ($m), Market Shares (%), 2012
Table 3.1 Members of FenaSaúde, 2013
Table 4.1 Brazilian Pharma Market Breakdown by Product Type: Revenues ($m), AGR (%),
CAGR (%), Market Share (%), 2012-2017
Table 4.2 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), Market
Shares (%), 2017
Table 4.3 Brazilian Market Breakdown by Product Type: Revenues ($m), AGR (%), CAGR (%),
Market Shares (%) 2018-2024
Table 4.4 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), Market
Shares (%), 2024
Table 4.5 Selected Technology Transfer Agreements in Brazil 1985-2013
Table 4.6 Patented Pharmaceuticals: Revenues ($m), AGR (%), CAGR (%), Market Share (%),
2012-2017
Table 4.7 Patented Pharmaceuticals: Revenues ($m), AGR (%), CAGR (%), 2018-2024
Table 4.8 Generic Pharmaceuticals: Revenues ($m), AGR (%), CAGR (%), Market Share (%),
2012-2017
Table 4.9 Generic Pharmaceuticals: Revenues ($m), AGR (%), CAGR (%), Market Share (%),
2018-2024
www.visiongain.com

10. Contents
Table 4.10 OTC Pharmaceuticals: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 20122017
Table 4.11 OTC Pharmaceuticals: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 20182024
Table 5.1 Brazilian Market Breakdown by Therapeutic Area: Revenues ($m), AGR (%), CAGR
(%), Market Shares (%) 2012-2017
Table 5.2 Therapeutic Area Breakdown: Revenues ($m), Market Share (%), 2017
Table 5.3 Brazilian Market Breakdown by Therapeutic Area: Revenues ($m), AGR (%), CAGR
(%), Market Shares (%) 2018-2024
Table 5.4 Therapeutic Area Breakdown: Revenues ($m), Market Shares (%), 2024
Table 5.5 CNS Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 20122017
Table 5.6 CNS Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 20182024
Table 5.7 Cardiovascular Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Share
(%), 2012-2017
Table 5.8 Cardiovascular Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Share
(%), 2018-2024
Table 5.9 Alimentary/Metabolic Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market
Share (%), 2012-2017
Table 5.10 Alimentary/Metabolic Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market
Share (%), 2018-2024
Table 5.11 Oncology Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Share (%),
2012-2017
Table 5.12 Oncology Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Share (%),
2018-2024
Table 5.13Infectious Disease Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market
Share (%), 2012-2017
Table 5.14 Infectious Disease Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market
Share (%), 2018-2024
www.visiongain.com

11. Contents
Table 6.1 Leading Domestic Companies in the Brazilian Market: Revenues ($m), Market Shares
(%), 2012
Table 6.2 EMS: Overview, 2013
Table 6.3 Medley: Overview, 2013
Table 6.4 Hypermarcas: Overview, 2013
Table 6.5 Aché: Overview, 2013
Table 6.6 Eurofarma: Overview, 2013
Table 6.7 Teuto: Overview, 2013
Table 6.8 Biolab Sanus: Overview, 2013
Table 6.9 Cristália: Overview, 2013
Table 6.10 Libbs: Overview, 2013
Table 6.11 Uniao Quimica: Overview, 2013
Table 7.1 Leading Multinational Companies in the Brazilian Market: Revenues ($m), Market
Shares (%), 2012
Table 7.2 Selected Multinational M&A Transactions in Brazilian Market, 2009-2012
Table 7.3 Sanofi: Overview, 2013
Table 7.4 Novartis: Overview, 2013
Table 7.5 Roche: Overview, 2013
Table 7.6 Merck: Overview, 2013
Table 7.7 Pfizer: Overview, 2013
Table 7.8 Bayer: Overview, 2013
Table 7.9 AstraZeneca: Overview, 2013
Table 7.10 Boehringer Ingelheim: Overview, 2013
Table 7.11 Takeda: Overview, 2013
Table 7.12 Merck Serono: Overview, 2013
Table 8.1 Brazilian Pharmaceutical Market: Strengths and Weaknesses, 2013
Table 8.2 Brazilian Pharmaceutical Market: Opportunities and Threats, 2013
Table 8.3 Brazilian Pharmaceutical Market: STEP Analysis, 2013-2024
www.visiongain.com

12. Contents
List of Figures
Figure 2.1 Brazilian Pharmaceutical Market: Revenues ($m), 2012-2024
Figure 2.2 Demographic Breakdown of Brazilian Population by Age, 2013
Figure 2.3 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), Market
Shares (%), 2012
Figure 2.4 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), Market
Shares (%), 2012
Figure 2.5 Leading Companies in the Brazilian Market: Revenues ($m), Market Shares (%), 2012
Figure 2.6 Leading National Markets Worldwide: Revenues ($m), Market Shares (%), 2012
Figure 2.7 Leading National Markets in Latin America: Revenues ($m), Market Shares (%), 2012
Figure 2.8 Leading National ‘Pharmerging’ Markets: Revenues ($m), 2012
Figure 2.9 BRIC National Markets: Revenues ($m), 2012
Figure 3.1 Public/Private Balance in Healthcare Provision, 2008
Figure 3.2 CMED-Mandated Maximum Drug Price Rises, 2009-2013
Figure 3.3 Distribution (%) of Revenues Among Brazilian Regions, 2012
Figure 4.1 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), Market
Shares (%), 2017
Figure 4.2 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), Market
Shares (%), 2024
Figure 4.3 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), 2012-2024
Figure 4.4 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), 2012,
2017, 2024
Figure 4.5 Biologics in the Brazilian Market: Product Mix Breakdown: Revenues ($m) and Shares
(%), 2012
Figure 4.6 Biologics in the Brazilian Market: Product Mix Breakdown: Revenues ($m), 2012,
2017 and 2024
Figure 4.7 Drivers and Restraints for Prescription Pharmaceuticals, 2013
Figure 4.8 Patented Pharmaceuticals: Revenues ($m), 2012-2024
Figure 4.9 Drivers and Restraints for Prescription Pharmaceuticals, 2013
www.visiongain.com

13. Contents
Figure 4.10 Generic Pharmaceuticals: Revenues ($m), 2012-2024
Figure 4.11 Drivers and Restraints for Generic Pharmaceuticals, 2013
Figure 4.12 OTC Pharmaceuticals: Revenues ($m), 2012-2024
Figure 5.1 Therapeutic Area Breakdown: Revenues ($m), Market Shares (%), 2017
Figure 5.2 Therapeutic Area Breakdown: Revenues ($m), Market Shares (%), 2024
Figure 5.3 Therapeutic Area Breakdown: Revenues ($m), 2012-2024
Figure 5.4 Therapeutic Area Breakdown: Revenues ($m), 2012, 2017, 2024
Figure 5.5 Drivers and Restraints for CNS Therapeutic Area, 2013
Figure 5.6 CNS Therapeutic Area: Revenues ($m), 2012-2024
Figure 5.7 Drivers and Restraints for Cardiovascular Therapeutic Area, 2013
Figure 5.8 Cardiovascular Therapeutic Area: Revenues ($m), 2012-2024
Figure 5.9 Drivers and Restraints for Alimentary/Metabolic Therapeutic Area, 2013
Figure 5.10 Alimentary/Metabolic Therapeutic Area: Revenues ($m), 2012-2024
Figure 5.11 Drivers and Restraints for Oncology Therapeutic Area, 2013
Figure 5.12 Oncology Therapeutic Area: Revenues ($m), 2012-2024
Figure 5.13 Drivers and Restraints for Infectious Disease Therapeutic Area, 2013
Figure 5.14 Infectious Disease Therapeutic Area: Revenues ($m), 2012-2024
Figure 6.1 Leading Domestic Companies in the Brazilian Market: Revenues ($m), Market Shares
(%), 2012
Table 7.1 Leading Multinational Pharma Companies in the Brazilian Market: Revenues ($m),
Market Shares (%), 2012
Figure 9.1 Brazilian Pharmaceutical Market: Revenues ($m), 2012-2017
Figure 9.2 Brazilian Pharmaceutical Market: Revenues ($m), 2018-2024
Figure 9.3 Product Mix: Revenues ($m), 2012-2017
Figure 9.4 Product Mix: Revenues ($m), 2018-2024
Figure 9.5 Top 10 Companies in the Brazilian Pharma Market, 2012
Figure 9.6 Therapeutic Areas: Revenues ($m) in Brazil, 2012-2017
Figure 9.7 Therapeutic Areas: Revenues ($m) in Brazil, 2018-2024
www.visiongain.com

14. Contents
Companies and Other Organisations Mentioned in Report
Abbott Laboratories
Abbott Laboratories (including Abbvie)
Achê Laboratórios Farmacêuticos
Actavis
Agência Nacional de Saude Suplementar
Agência Nacional de Vigilância Sanitária (ANVISA)
Agila Specialties
AlfaRio
Alliance Boots
Allianz Health
AMB (Brazilian Medical Association)
American Diabetes Association
American Varian Medical Systems
Amgen
Amil Participações
Antaris Consulting
Arena Pharmaceuticals
Arseus
Associação Brasileira da Indústria de Medicamentos Isentos de Prescrição (ABIMIP)
Associação Brasileira das Redes de Farmácias e Drogarias (ABRAFARMA)
Associação Brasileira de Reabilitação de Coluna
Associacao da Industria Farmaceutica de Pesquisa (InterFarma)
Associação Nacional de Assistencia ao Diabetico (ANAD)
Astellas
AstraZeneca
Athos Pharma
Axis Biotec
Baxter
Bayer
www.visiongain.com

15. Contents
BD
Biocon
Biogen Idec
Biolab Emcure
Biolab-Sanus Farma
Biomm
Bionovis
Biosidus
Biovail Corporation
Boehringer Ingelheim
Boiron
Bradesco Saúde
Brainfarma Industria e Farmaceutica
Brasil Pharma
Brazilian Development Bank (BNDES)
Bristol-Myers Squibb
BTG Pactual
Bunker Industria Farmaceutica
Caixa Seguros
Câmara de Regulação do Mercado de Medicamentos (CMED)
Cannes RJ Participacoes
Castro Marques Group
Celesio
Chemo
Claris Lifesciences
CMED
Comissão Nacional de Incorporação de Tecnologia (CONITEC)
Comitê Técnico Assessor de Imunizações (CTAI)
Conselho Administrativo de Defesa Econômica
Corporacion Infarmasa
www.visiongain.com

16. Contents
CPhI Worldwide
CVS Pharmacy
Daiichi Sankyo
Datamatrix
Delta Instituto Terapeutico
Dimed
Disaq Pharmaceuticals
DM Industria Farmaceutica
Dong-A
DPSP
Drogarias Tamoio
Eisai
Eli Lilly
Emcure
EMS
Eurofarma
Everis
Excel RX
FarmaBrasil group
Farmácia Popular
Farmadacta Informatica
Farmais
Far-Manguinhos
Farmindustria
FDA
Federação Nacional de Saúde Suplementar
Federal Council of Medicine (CFM)
Fiocruz
Food and Drug Administration (US FDA)
Forest Laboratories
www.visiongain.com

17. Contents
GE
Genfar
Genzyme
Germed Pharma
Gilead Sciences
GlaxoSmithKline (GSK)
Glenmark
Golden Cross Assistance
Grünenthal
Grupo Bradesco
Grupo Cimed
Guararapes
Health Canada
Hebron
Hemobrás
Hospital das Clínicas
Hospital Israelita Albert Einstein
Hospital Santa Catarina
Hypermarcas
IMA Laboratories
Indian Council of Medical Research
Infectious Disease Research Institute (IDRI)
Institut Pasteur
Instituto Butantan
Instituto de Estudos de Saúde Suplementar (IESS)
Interagile Propaganda e Promocoes
Intermédica
Itauseg Health
Johnson & Johnson (J&J)
Kenya Medical Research Institute
www.visiongain.com

18. Contents
Laboratorio Cristália
Laboratório Daudt Oliveira
Laboratório Farmaceutico do Estado de Pernambuco (LAFEPE)
Laboratorio Quimico Farmaceutico Bergamo
Laboratorio Teuto Brasileiro
Laboratorios Gautier
Laboratórios Kendrick
Laboratórios Klinger Do Brasil
Laramara
Legrand
Libbs Farmacêutica
Locafarma Solucoes de Transportes e Logistica
Luper Indústria Farmacêutica
Mais Econômica
Mantecorp Industria Quimica e Farmaceutica
Maritima Seguros
Mayne Pharma
Médecins sans Frontières
Medley
Meizler Biopharma
Melcon
Merck & Co.
Merck Serono
Merz Pharma
Metlife Dental Plans
Minas Gerais State Department of Health
Ministério da Saúde (Ministry of Health, Brazil)
moksha8
Multilab Industria e Comercio de Produtos Farmaceuticos
Mylan
www.visiongain.com

19. Contents
Nature's Plus Farmaceutica
Neo Química
Neuberger Machines
Novartis
Novo Nordisk
Nycomed
Odontoprev Omint Health Services
Oncoprod
Optimer Pharmaceuticals
Orygen Biotecnologia
Oswaldo Cruz Foundation
Otsuka
Pan American Health Organization
Panarello
Panpharma
Pasteur Institute
Pele Nova
Penha
Pfizer
Pharmaceutical Product Development, LLC (PPD)
PharmaPraxis
Porto Seguro
Probiomed
Probiotica
Procter & Gamble
Profarma
Pró-Genéricos
Promovendas Representacoes
Protalix BioTherapeutics
Quesada Farmaceutica
www.visiongain.com

20. Contents
Quintiles
RaiaDrogasil
Ranbaxy
Reckitt Benckiser
Regional Council of Medicine, State of São Paulo
Roche
Rosário
Sabin Vaccine Institute
Sandoz
Sanofi
Sant’Ana
Santa Cruz
Shasun Pharma
Siemens
Sincamesp
Sinclair IS Pharma
Sindusfarma
Sistema Único de Saude (SUS)
Strides Arcolab
SulAmérica
Sun
Supera Farma Laboratorios
Takeda
Telefônica Digital
Tempo Participações
Teva Pharmaceutical industries
TKS Farmaceutica
Torrent
Toshiba
UCB
www.visiongain.com

21. Contents
UERJ
UFMG
UFRJ
Uniao Quimica
UNICAMP
UNIFESP
Unimed Seguros
UnitedHealth
University of São Paulo
Valeant
Varian Medical Systems
Volta
Walgreens
Watson Pharmaceuticals (now Actavis)
Wheaton Brazil
Wockhardt
World Health Organization (WHO)
Zydus Cadila
www.visiongain.com

22. Brazilian Pharmaceutical Market
2014-2024
5.4.4 The Heart Disease Opportunity Over the Next 10 Years
Figure 5.7 indicates drivers and restraints for the cardiovascular therapeutic area in Brazil.
Figure 5.7 Drivers and Restraints for the Cardiovascular Therapeutic Area, 2013
Restraints
Patent expiries for statin drugs take away a key
revenue driver for the therapeutic area
Very high prevalence of cardiovascular disease,
with strokes and heart attacks likely to rise
sharply over the forecast period
Government access to hypertension treatments
allows major take-up for this leading unmet
medical need
Awareness of hypertension remains low among
the population
Heavy OTC use may restrict opportunities for
more expensive Rx drugs
Significant interest from companies at home and
abroad
Drivers
Source: visiongain 2013
The main driver for the cardiovascular therapeutic area lies simply in the vast levels of medical
need in the country. If, as some estimates suggest, almost 60 million Brazilians suffer from some
form of cardiovascular condition (principally hypertension), then this is a major commercial
opportunity. The difficulty comes in the fact that the majority of cardiovascular treatments are
preventative and depend on good information for personal health management on the part of the
population. Since many of the most important cardiovascular drugs have also lost patent
protection, the growth of the generics segment will be a necessary factor in the continued
expansion of this therapeutic area. For example, generic simvastatin is a market leader, and other
generic statins and other molecules will become key drivers in the near-term. The widespread use
of OTC cardiovascular treatments may be a restraint on the market inasmuch as it restricts use of
the major prescription drugs.
5.4.5 Market Forecast for Cardiovascular Therapeutic Area 2014-2024
The cardiovascular therapeutic field will expand with a five-year CAGR of 6% to achieve 2017
revenues of $6211m. Over this period, its market share will decline from 17% to 15%. See Table
5.7. By 2024, revenues for the therapeutic area will reach $8790m, with a CAGR of 6% across the
forecast period as a whole. See Table 5.7, Table 5.8 and Figure 5.8.
www.visiongain.com
Page 79

23. Brazilian Pharmaceutical Market
2014-2024
Table 5.7 Cardiovascular Therapeutic Area: Revenues ($m), AGR (%), CAGR (%),
Market Share (%), 2012-2017
2012
Revenues ($m )
2013
2014
2015
2016
2017
4544
4865
5237
5566
5914
6211
7
8
6
6
5
AGR (%)
CAGR (%, 2012-2017)
Market share (%)
6
17
16
16
16
16
15
Source: visiongain 2013
Table 5.8 Cardiovascular Therapeutic Area: Revenues ($m), AGR (%), CAGR (%),
Market Share (%), 2018-2024
2018
2019
2020
2021
2022
2023
2024
Revenues ($m )
6570
6931
7280
7561
7975
8366
8790
AGR (%)
6
5
5
4
5
5
5
CAGR (%, 2018-2024)
5
CAGR (%, 2012-2024)
6
Market share (%)
15
14
14
14
14
13
13
Source: visiongain 2013
5.5 Alimentary/Metabolic Diseases: Affecting More Than a Third of
Brazilians
Prevalence of alimentary/metabolic conditions in Brazil is high, with over a quarter of the
population suffering from gastrointestinal conditions including gastroesophageal reflux disease and
inflammatory bowel conditions. Two of the top-selling generic drugs in the country in H1 2013 were
pantoprazole and omeprazole, the proton pump inhibitors for reducing stomach acid, which jointly
accrued over $90m in revenues for that six-month period. Diabetes is also a major issue in
Brazilian healthcare, with WHO estimates indicating that prevalence will increase by two-thirds
between 2010 and 2030. Since 2006, diabetes treatments are now distributed free via the
Farmácia Popular channel discussed previously.
www.visiongain.com
Page 80